Fractyl Health (GUTS) Research & Development (2023 - 2026)

Fractyl Health (GUTS) has reported Research & Development for 4 consecutive years, with $13.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development fell 34.7% year-over-year to $13.8 million; the trailing twelve-month figure through Jun 2026 stood at $63.4 million (down 20.67% YoY), and the FY2025 full-year result was $74.5 million, up 5.77% from the prior year.
• Research & Development was $13.8 million for Q2 2026 at Fractyl Health, down from $15.6 million in the prior quarter.
• The five-year high for Research & Development was $21.2 million in Q2 2025, with the low at $9.1 million in Q2 2023.
• Historically, Research & Development has averaged $15.2 million across 4 years, with a median of $16.0 million in 2025.
• Annual changes were most pronounced in 2024 — Research & Development soared 102.56% — and 2026, when it slumped 34.7%.
• Tracing GUTS's Research & Development over 4 years: stood at $10.2 million in 2023, then surged by 99.5% to $20.3 million in 2024, then decreased by 18.68% to $16.5 million in 2025, then slipped by 16.26% to $13.8 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $13.8 million in Q2 2026, $15.6 million in Q1 2026, and $16.5 million in Q4 2025.